-
APL-1202 combined with PD-1 neoadjuvant therapy for MIBC completed the first enrollment in phase II trial
Time of Update: 2022-12-29
SH) announced that its oral drug APL-1202 combined with tislelizumab neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) clinical trial has recently completed the enrollment of the first patient in the phase II clinical trial.
-
Warner Pharmaceutical has another variety review! In the first three quarters, the company had 6 product reviews, and 2 won the first one
Time of Update: 2022-12-29
In addition, Warner Pharmaceutical also submitted supplementary applications for consistency evaluation of ferrous succinate tablets, lipoic acid injection, nifedipine sustained-release tablets, ornidazole injection and other products.
In addition, Warner Pharmaceutical also submitted supplementary applications for consistency evaluation of ferrous succinate tablets, lipoic acid injection, nifedipine sustained-release tablets, ornidazole injection and other products.
-
Clinical data on KN026 in combination with docetaxel for neoadjuvant therapy for HER2-positive early or locally advanced breast cancer are published at SABCS 2022
Time of Update: 2022-12-29
About KN026 KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can bind two non-overlapping epitopes of HER2 at the same time, resulting in HER2 signal blockade, which is better than the combination of trastuzumab and pertuzumab, such as showing higher affinity, and has a potent tumor suppressor effect in HER2-positive tumor cell lines.
-
The cross-border wind does not stop, and Tongrentang is laying out the "drinking" market
Time of Update: 2022-12-29
【Pharmaceutical Network Enterprise News】Recently, Tongrentang announced that the company plans to sign investment agreements with Hubei Chuyuan Spring Wine Industry Co.
【Pharmaceutical Network Enterprise News】Recently, Tongrentang announced that the company plans to sign investment agreements with Hubei Chuyuan Spring Wine Industry Co.
-
Innovent announces the results of the Phase III clinical study (CREDIT-1) of tolesimab (IBI306) in patients with non-familial hypercholesterolemia at the 2022 American Heart Association Annual Meeting (AHA 2022).
Time of Update: 2022-12-04
, announced: Innovent Biologics independently developed anti-proprotein converting enzyme subtilisin 9 (PCSK-9) monoclonal antibody (toleximab, R&D code: IBI306) The results of the Phase III clinical study (study code: CREDIT-1) in patients with non-familial hypercholesterolemia in China were accepted as conference abstracts and published in poster form (number: VP173) at the 2022 American Heart Association Annual Meeting (AHA 2022).
-
The Phase III clinical trial of Ahong's bladder cancer diagnosis and surgical drug Hycway achieved the enrollment of the first patient
Time of Update: 2022-12-04
SH) announced on November 7 that its drug for the diagnosis and surgery of bladder cancer has completed the enrollment of the first patient in the phase III clinical trial.
-
Ascletis announces a posterior report on a Phase I single-dose study of ASC43F for the treatment of NASH at the 2022 American Association for the Study of Liver Disease Annual Meeting
Time of Update: 2022-12-04
The following is a summary of the summary: : A Phase I single-dose study to evaluate the safety, tolerability, and pharmacokinetics of ASC43F (a fixed-dose combination oral tablet consisting of the thyroid hormone receptor beta agonist ASC41 and the farnesol X receptor agonist ASC42) in healthy subjects Abstract/poster number: 2314 Category: Nonalcoholic fatty liver disease treatment Study Design: ASC43F-101 (NCT05118516) is an open-label, single-dose phase I study in healthy subjects.
-
The landmark EMPA-KIDNEY trial showed that in patients with chronic kidney disease, empagliflozin significantly reduced the risk of renal disease progression or cardiovascular death by up to 28% compared with placebo
Time of Update: 2022-11-26
The EMPA-KIDNEY PHASE III clinical trial demonstrated significant renal and cardiovascular benefits in adult patients with chronic kidney disease (CKD), meeting its primary endpoints [1],[2].
The EMPA-KIDNEY PHASE III clinical trial demonstrated significant renal and cardiovascular benefits in adult patients with chronic kidney disease (CKD), meeting its primary endpoints [1],[2].
-
Mengke Pharma's new drug MRX-8, a new anti-drug resistant bacteria, completed the first subject dosing in China
Time of Update: 2022-11-26
("Mengke Pharmaceutical", 688373) announced that its self-developed new drug against gram-negative resistant bacteria MRX-8 China Phase I clinical trial completed the dosing of the first subject.
("Mengke Pharmaceutical", 688373) announced that its self-developed new drug against gram-negative resistant bacteria MRX-8 China Phase I clinical trial completed the dosing of the first subject.
-
Novavax prototype seedlings can be used as a booster
Time of Update: 2022-11-26
The seedlings were created using Novavax recombinant nanoparticle technology to generate antigens derived from the coronavirus spike protein, while also formulated using Novavax's patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate the production of high levels of neutralizing antibodies.
-
Genting Sun Yew announced that its mRNA vaccine candidate has achieved positive top-line results in the adult primary immunization phase II trial, and is submitting a Phase III clinical trial application for booster vaccine vaccine overseas, with a local manufacturing facility soon to be operational
Time of Update: 2022-11-15
The geometric mean titer (GMT) ratio of neutralizing antibodies observed two weeks after the second intramuscular injection of PTX-COVID19-B was statistically non-inferior in terms of Comirnaty®, an FDA-approved mRNA vaccine (jointly developed by Pfizer and BioNTech).
-
Daewoong Pharmaceutical Pharmaceutical announced the results of a phase III clinical trial of a new diabetes drug "Enavog-liflozin"
Time of Update: 2022-11-15
Daewoong (CEO Sengho Jeon and Changjae Lee) announced on October 31 that at the 2022 International Congress on Diabetes and Metabolism ("ICDM 2022") held at the Svisgrande Hotel in Seoul from October 7 to 8, the company disclosed its treatment for Enavog-liflozin monotherapy, Enavog-liflozin-metformin dual therapy, and the results of three phase III clinical trials of Enavog-liflozin-metformin-gemigliptin triple therapy.
-
Results of a global phase III clinical trial of nintedanib in the treatment of progressive fibrotic interstitial lung disease in children and adolescents were announced
Time of Update: 2022-11-15
In September, Boehringer Ingelheim announced positive results from a global Phase III clinical trial of Nintedanib™ for the treatment of children and adolescents aged 6-17 years with progressive fibrotic interstitial lung disease, reaching the primary composite endpoint.
-
【AASLD 2022】Selected for oral presentation! Ascentage Pharma will present the clinical progress of IAP antagonist APG-1387 in the treatment of chronic hepatitis B at the American Society of Liver Disease Annual Meeting
Time of Update: 2022-11-15
": First human trial of apoptosis protein inhibitor antagonist APG-1387 in the treatment of chronic hepatitis B Title: First-in-Human Study of APG-1387, Targeting Inhibitor of Apoptosis Proteins, For the Treatment of Patients with Chronic Hepatitis BAbstract number: 32Session 2: Novel Therapeutic Approaches Aimed at Functional Cure of Hepatitis B and DReported: Sunday, November 6, 2022 9:00-10:30 AM ESTReporting venue: Walter.
-
Tengsheng Bo Yao announced positive clinical data at IDWeek 2022 to support the continued development of current novel HIV treatment candidates
Time of Update: 2022-11-15
S. volunteers, two candidate candidates for the treatment of human immunodeficiency virus (HIV) infection 。 Both studies suggest that BRII-732 and BRII-778 are safe and well tolerated when administered weekly, providing important data support for potential first-in-class oral once-weekly HIV combination therapies under development.
-
Ascletis announced that the new crown oral drug 3CLpro inhibitor ASC11 has submitted a clinical trial application for new drugs in the United States
Time of Update: 2022-11-15
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that it has submitted an application for a new drug clinical trial (IND) for ASC11, an oral drug candidate, protease (3CLpro) inhibitor, following a pre-IND consultation.
-
Recombinant herpes zoster epidemic Miao Xin Anlishi is able to provide protection for adults aged 50 years and older for at least 10 years
Time of Update: 2022-11-15
GlaxoSmithKline (GSK) today announced positive interim results from the ZOSTER-049 expansion study: initial vaccination against recombinant herpes zoster disease Miao Xin Anli provides at least 10 years of shingles protection [1].
-
The clinical trial application of Mabwell's innovative drug 9MW3011 injection was accepted by the NMPA
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Mabwell (stock code: 688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell (stock code: 688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell (stock code: 688062.
js?cdnversion='+~(-new Date()/36e5)];Mabwell (stock code: 688062.
The 9MW3011 indication is intended to include a variety of diseases classified as rare diseases in different parts of the world, such as β-thalassemia, polycythemia vera and other ironostatic related diseases.
-
Chengyi Biologics announced that the GLP-1 receptor agonist ECC5004 has been approved for clinical trial in the United States
Time of Update: 2022-11-15
, Ltd. recently announced that the US Food and Drug Administration (FDA) has approved its application for a clinical trial of the glucagon-like peptide 1 (GLP-1) receptor agonist ECC5004 in the United States for the treatment of type 2 diabetes mellitus (T2DM).
-
Ten orelabrutinib studies were selected for the 64th Annual Meeting of the American Society of Hematology (ASH).
Time of Update: 2022-11-14
m. ET First author: Zhao Shihua Corresponding author: Huang Wenrong Poster Presentation 1 ：A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Diagnosed Primary Central Nervous System Lymphoma A multicenter, single-arm, prospective phase II study of orelabrutinib combined with high-dose methotrexate and rituximab sequential autologous hematopoietic stem cell transplantation in the treatment of primary central nervous system lymphoma Abstract code: 1624 Breakout Venue: 626.
